Nyxoah (NYXH) Current Deferred Revenue (2024 - 2025)
Nyxoah's (NYXH) quarterly Current Deferred Revenue came in at $1.0 million in Q4 2025, up 732.35% year-on-year from $125025.7 in Q4 2024, and up 99.86% quarter-over-quarter from $520701.5 in Q2 2025.
Nyxoah (NYXH) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Nyxoah's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2025.
- On a quarterly basis, Current Deferred Revenue rose 732.35% year-over-year to $1.0 million in Q4 2025; TTM through Dec 2025 was $1.0 million, a 732.35% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 732.35% from the prior year.
- Current Deferred Revenue advanced to $1.0 million in Q4 2025 per NYXH's latest filing, from $520701.5 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.0 million in Q4 2025 and bottomed at $125025.7 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn |
| 10 | Nyxoah | 56.02 Mn | 103.00 Mn | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.04 Mn |
| Jun 30, 2025 | 520,701.46 |
| Mar 31, 2025 | 387,093.47 |
| Dec 31, 2024 | 125,025.66 |